MA33285B1 - Anticorps anti-cxcr4 pour le traitement du vih - Google Patents

Anticorps anti-cxcr4 pour le traitement du vih

Info

Publication number
MA33285B1
MA33285B1 MA34368A MA34368A MA33285B1 MA 33285 B1 MA33285 B1 MA 33285B1 MA 34368 A MA34368 A MA 34368A MA 34368 A MA34368 A MA 34368A MA 33285 B1 MA33285 B1 MA 33285B1
Authority
MA
Morocco
Prior art keywords
cxcr4
hiv
treatment
antibodies
relates
Prior art date
Application number
MA34368A
Other languages
Arabic (ar)
English (en)
Inventor
Christine Klinguer-Hamour
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41060014&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA33285(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of MA33285B1 publication Critical patent/MA33285B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention porte sur de nouveaux anticorps isolés, ou les composés dérivés ou les fragments fonctionnels de ceux-ci, aptes à se fixer au CXCR4 mais également à induire un changement de conformation des homodimères de CXCR4 et aptes à inhiber la réplication d'isolats primaires du VIH-1 dans les PBMC. Plus particulièrement, la présente invention porte sur les anticorps monoclonaux 515H7 et 301aE5, spécifiques vis-à-vis de la protéine CXCR4, ainsi que sur leur utilisation pour le traitement d'une infection à VIH. L'invention porte également sur des compositions pharmaceutiques composées de tels anticorps et sur un procédé pour la sélection de tels anticorps.
MA34368A 2009-04-29 2010-04-29 Anticorps anti-cxcr4 pour le traitement du vih MA33285B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17368009P 2009-04-29 2009-04-29
EP09159076A EP2246364A1 (fr) 2009-04-29 2009-04-29 Anticorps anti CXCR4 pour le traitement du VIH
PCT/EP2010/055863 WO2010125162A1 (fr) 2009-04-29 2010-04-29 Anticorps anti-cxcr4 pour le traitement du vih

Publications (1)

Publication Number Publication Date
MA33285B1 true MA33285B1 (fr) 2012-05-02

Family

ID=41060014

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34368A MA33285B1 (fr) 2009-04-29 2010-04-29 Anticorps anti-cxcr4 pour le traitement du vih

Country Status (25)

Country Link
US (3) US9090686B2 (fr)
EP (2) EP2246364A1 (fr)
JP (1) JP5800802B2 (fr)
KR (1) KR20120039525A (fr)
CN (1) CN102459343B (fr)
AU (1) AU2010243526B2 (fr)
BR (2) BRPI1011540A2 (fr)
CA (1) CA2759989A1 (fr)
CL (1) CL2011002664A1 (fr)
CO (1) CO6390114A2 (fr)
ES (1) ES2534313T3 (fr)
GE (1) GEP20146181B (fr)
HU (1) HUE025083T2 (fr)
IL (1) IL215919A0 (fr)
MA (1) MA33285B1 (fr)
MX (1) MX2011011285A (fr)
MY (1) MY155400A (fr)
NZ (1) NZ596712A (fr)
PL (1) PL2424897T3 (fr)
RU (1) RU2573902C2 (fr)
SG (1) SG175353A1 (fr)
TN (1) TN2011000534A1 (fr)
UA (1) UA107929C2 (fr)
WO (1) WO2010125162A1 (fr)
ZA (1) ZA201108330B (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2371863A1 (fr) * 2010-03-30 2011-10-05 Pierre Fabre Médicament Anticorps humanisé anti CXCR4 pour le traitement du cancer
RU2013122770A (ru) * 2010-10-27 2014-12-10 Пьер Фабр Медикамент Антитела для лечения вич
EP3252076B1 (fr) 2011-01-14 2019-09-04 The Regents Of The University Of California Utilisation diagnostique d' anticorps thérapeutiques contre la protéine ror-1
US20140120555A1 (en) * 2011-06-20 2014-05-01 Pierre Fabre Medicament Anti-cxcr4 antibody with effector functions and its use for the treatment of cancer
ES2758884T3 (es) 2011-06-24 2020-05-06 Stephen D Gillies Proteínas de fusión de inmunoglobulina a través de cadena ligera y métodos de uso de ellas
AR087363A1 (es) * 2011-07-29 2014-03-19 Pf Medicament Uso del anticuerpo i-3859 para la deteccion y diagnostico de los canceres
JP2017501986A (ja) 2013-12-02 2017-01-19 アーロン ダイアモンド エイズ リサーチ センター ネイティブな構成を有する二重特異性抗体を使用した細胞レセプターアンカリングによる改善されたｈｉｖ−１中和抗体の効力及び幅
US10308707B2 (en) 2013-12-02 2019-06-04 Aaron Diamond Aids Research Center Bispecific HIV-1-neutralizing antibodies
MA44077A (fr) 2015-12-15 2021-05-05 Gilead Sciences Inc Anticorps neutralisants le virus de l'immunodéficience humaine
TWI640536B (zh) 2016-06-20 2018-11-11 克馬伯有限公司 抗體
US10882907B2 (en) 2017-06-21 2021-01-05 Gilead Sciences, Inc. Multispecific antibodies that target HIV GP120 and CD3
US11180575B2 (en) 2018-12-28 2021-11-23 Corn Products Development, Inc. Thermally inhibited starch and process for making
KR102825164B1 (ko) 2018-03-27 2025-06-26 브리스톨-마이어스 스큅 컴퍼니 자외선 신호를 사용한 단백질 농도의 실시간 모니터링
CN111214650A (zh) * 2018-11-23 2020-06-02 广州溯原生物科技有限公司 一种hiv抗原-受体三聚体复合物的解离因子的应用
WO2020172658A1 (fr) 2019-02-24 2020-08-27 Bristol-Myers Squibb Company Procédés d'isolement d'une protéine
US20220220430A1 (en) 2019-05-23 2022-07-14 Bristol-Myers Squibb Company Methods of monitoring cell culture media
JP2023511331A (ja) * 2020-01-16 2023-03-17 カイロス セラピューティクス， インコーポレイテッド 骨髄腫細胞および卵巣がん細胞に特異的なヒト化抗体
US20230374064A1 (en) 2020-10-05 2023-11-23 Bristol-Myers Squibb Company Methods for concentrating proteins
JP2025509274A (ja) 2022-03-09 2025-04-11 ブリストル－マイヤーズ スクイブ カンパニー 治療用タンパク質の一過性発現
US12006353B2 (en) * 2022-07-25 2024-06-11 Long Chen Application of SCFV protein, car gene expression vector, CAR-T cell and application thereof
CN115724993A (zh) * 2022-07-26 2023-03-03 陈龙 Scfv蛋白的应用、car基因表达载体、car-t细胞及应用
TW202430550A (zh) 2022-10-18 2024-08-01 日商明治製菓藥業股份有限公司 Ｔ細胞性腫瘤之治療劑

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8924581D0 (en) 1989-11-01 1989-12-20 Pa Consulting Services Bleaching of hair
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
JPH05505112A (ja) * 1990-11-27 1993-08-05 バイオジェン，インコーポレイテッド Ａｉｄｓ、ａｒｃおよびｈｉｖ感染の予防および治療に有用な抗ｃｄ４抗体ホモログ
WO1994004679A1 (fr) 1991-06-14 1994-03-03 Genentech, Inc. Procede pour fabriquer des anticorps humanises
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
CA2145278C (fr) * 1992-09-25 2009-03-10 Commonwealth Scientific And Industrial Research Organisation Polypeptide liant cible
US6197578B1 (en) * 1996-01-30 2001-03-06 The United States Of America As Represented By The Department Of Health And Human Services Cells expressing both human CD4 and a human fusion accessory factor associated with HIV infection
AU2841101A (en) * 1999-12-08 2001-06-18 Novartis Ag Methods and compositions useful for inhibiting ccr5-dependent infection of cellsby hiv-1
US7321026B2 (en) * 2001-06-27 2008-01-22 Skytech Technology Limited Framework-patched immunoglobulins
US20040093621A1 (en) * 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
RU2006102570A (ru) * 2003-06-30 2007-08-20 Био-Текнолоджи Дженерал(Израиль) Лтд. (IL) Антитела и их применение
US20080039428A1 (en) * 2006-06-29 2008-02-14 Panacos Pharmaceuticals, Inc. Antiretroviral combination therapy
ATE550355T1 (de) * 2006-09-29 2012-04-15 Hoffmann La Roche Antikörper gegen ccr5 und ihre verwendung
CA2679266A1 (fr) * 2007-02-27 2008-09-04 Forerunner Pharma Research Co., Ltd. Composition pharmaceutique comportant un anticorps anti-grp 78 en tant qu'ingredient actif
KR20100133012A (ko) * 2008-05-14 2010-12-20 일라이 릴리 앤드 캄파니 항-ｃｘｃｒ4 항체
EP2172485A1 (fr) * 2008-10-01 2010-04-07 Pierre Fabre Medicament Nouveaux anticorps anti CXCR4 et leur utilisation dans le traitement contre le cancer
BR112012010252A2 (pt) * 2009-10-29 2016-12-06 Janssen Biotech Inc variantes de glicosilação de anticorpo
EP2371863A1 (fr) * 2010-03-30 2011-10-05 Pierre Fabre Médicament Anticorps humanisé anti CXCR4 pour le traitement du cancer

Also Published As

Publication number Publication date
SG175353A1 (en) 2011-11-28
JP5800802B2 (ja) 2015-10-28
HK1165813A1 (en) 2012-10-12
CO6390114A2 (es) 2012-02-29
CA2759989A1 (fr) 2010-11-04
RU2573902C2 (ru) 2016-01-27
NZ596712A (en) 2013-10-25
HUE025083T2 (en) 2016-02-29
RU2011148077A (ru) 2013-06-10
CN102459343B (zh) 2015-09-16
GEP20146181B (en) 2014-10-27
EP2424897A1 (fr) 2012-03-07
US20160031995A1 (en) 2016-02-04
UA107929C2 (en) 2015-03-10
WO2010125162A1 (fr) 2010-11-04
US20110088104A1 (en) 2011-04-14
US9090686B2 (en) 2015-07-28
ZA201108330B (en) 2012-09-26
BRPI1011540A2 (pt) 2019-04-30
US20130174288A1 (en) 2013-07-04
AU2010243526B2 (en) 2015-02-12
AU2010243526A1 (en) 2011-12-22
EP2246364A1 (fr) 2010-11-03
BR112013009984A2 (pt) 2017-07-18
IL215919A0 (en) 2011-12-29
MX2011011285A (es) 2012-01-20
EP2424897B1 (fr) 2015-01-07
MY155400A (en) 2015-10-15
JP2012525129A (ja) 2012-10-22
KR20120039525A (ko) 2012-04-25
ES2534313T3 (es) 2015-04-21
CL2011002664A1 (es) 2012-12-14
PL2424897T3 (pl) 2015-07-31
CN102459343A (zh) 2012-05-16
TN2011000534A1 (en) 2013-05-24

Similar Documents

Publication Publication Date Title
MA33285B1 (fr) Anticorps anti-cxcr4 pour le traitement du vih
MA32928B1 (fr) Anticorps anti-cxcr4 et leur utilisation pour le traitement du cancer
MA34175B1 (fr) Anticorps anti-cxcr4 humanisés pour le traitement de cancer
BRPI0619357A8 (pt) Anticorpos monoclonais, composição farmacêutica, vacina, uso dos mesmos para tratamento ou prevenção de doença de alzheimer, métodos in vitro para diagnosticar e para identificar compostos apropriados para imunização de doença de alzheimer e kits
MA30876B1 (fr) Anticorps de la lymphotoxine-alpha
MA31500B1 (fr) Composes chimiques
MA31899B1 (fr) Anticorps monoclonaux qui se lient au hgm-csf et compositions medicales les comprenant
MA40041B1 (fr) Anticorps anti-gitr et leurs procédés d'utilisation
MA38161A1 (fr) Anticorps anti-bmp-6
MA30163B1 (fr) Anticorps monoclonaux specifiques pour a beta 1-42 ayant des proprietes therapeutiques
MA28982B1 (fr) Anticorps antagonistes de il-17
MA30353B1 (fr) Anticorps se liant à la protéine tyrosine phosphatase bêta humaine (hptpbêta) et utilisations correspondantes.
MA29374B1 (fr) Anticorps anti-ccr5 et leurs utilisations
EP2016173A4 (fr) Procédés et compositions de traitement d'infections par le virus de l'immunodéficience humaine avec des anticorps ou des fragments d'anticorps conjugués
EP1450857A4 (fr) Anticorps de neutralisation a activite sensiblement croisee contre le virus vih selectionnes a l'aide de complexes de co-recepteurs de env-cd4
MA30345B1 (fr) Formulation d'anticorps monoclonal humain anti-igf-1r
MA29226B1 (fr) Anticorps diriges contre le recepteur alpha 1 de il-13 et leurs utilisations
MA35659B1 (fr) Protéine de liaison à un antigène et son utilisation comme produit d'adressage pour le traitement du cancer
PE20241623A1 (es) Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y usos de los mismos
BRPI0518994A2 (pt) anticorpos ou polipeptÍdeos que se ligam a br3, seus usos e formulaÇÕes lÍquidas
MA30891B1 (fr) Nouveaux anticorps anti-proliferation
MA30671B1 (fr) Vaccins contre le paludisme
EP3781585A4 (fr) Dosages in vitro sensibles pour des préférences de substrat et de sites d'agents de liaison, de modification et de clivage d'acide nucléique
MA33381B1 (fr) Proteine de liaison a il-13
BR112012016309A2 (pt) "porção, composição farmacêutica, uso de uma quantidade eficaz da porção, método para identificar uma porção que se liga a um domínio semelhante a ig de um receptor do fator de crescimento endotelial vascular (receptor de vegf), e, anticorpo isolado ou uma porção de ligação de antígeno deste".